-
The Centers for Disease Control and Prevention (CDC) has issued new interim guidance for use of pre-exposure prophylaxis (PrEP) for in heterosexual men and women at high risk for HIV.
-
Findings from a just-published study of young women ages 13-16 in Cincinnati are the first to document herd protection after introduction of the human papillomavirus (HPV) vaccine.
-
The North American Menopause Society, the American Society for Reproductive Medicine, and The Endocrine Society have issued a joint statement concluding that hormone therapy (HT) is still an acceptable treatment for menopausal symptoms.
-
Two sister studies have been launched in Africa to evaluate the ability of a new monthly vaginal ring containing the antiretroviral drug dapivirine to safely prevent new HIV infections in women.
-
Update your practice: The Centers for Disease Control and Prevention (CDC) no longer recommends the oral antibiotic cefixime as a first-line treatment option for gonorrhea due to possible drug resistance.
-
The authors performed a nested case-control study using data from the Rochester Epidemiology Project which conducts population-based studies of the residents of Olmsted County, Minnesota.
-
In this issue: Zolpidem and risk of falls; AVR and anticoagulation; statins in cancer patients; and FDA actions.
-
Data were accessed from the nurses health study, which enrolled 121,700 U.S. female registered nurses who were 30-55 years old at the outset in 1976. Every 2 years, participants provided information about their lifestyle, medical history, and illnesses via mailed questionnaires.
-
To evaluate the effectiveness of mammography as a screening test, the authors used the Surveillance, Epidemiology, and End Results (SEER) database to examine trends from 1976 through 2008 in the incidence of early-stage breast cancer (ductal carcinoma in situ and localized disease) and late-stage breast cancer (regional and distant disease) among women 40 years of age or older in the United States.
-
